February 5, 2021 07:27 AM ESTUpdated February 8, 03:47 PM
R&D
FDA+

PTC whiffs on an­oth­er Duchenne study, plans to go to FDA again any­way

Jason Mast

Editor

Once again PTC Ther­a­peu­tics’ Duchenne mus­cu­lar dy­s­tro­phy drug has failed a clin­i­cal tri­al. And once again Stu­art Peltz and his crew are try­ing to use …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times